Therapeutic intersections: Expanding benefits of CD19 CAR T cells from cancer to autoimmunity

Heather M Sosnoski; Avery D Posey Jr

doi:10.1016/j.stem.2024.03.006

Therapeutic intersections: Expanding benefits of CD19 CAR T cells from cancer to autoimmunity

Cell Stem Cell. 2024 Apr 4;31(4):437-438. doi: 10.1016/j.stem.2024.03.006.

Authors

Heather M Sosnoski¹, Avery D Posey Jr²

Affiliations

¹ Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
² Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA. Electronic address: aposey@pennmedicine.upenn.edu.

PMID: 38579681
DOI: 10.1016/j.stem.2024.03.006

Abstract

Anti-CD19 CAR T cells were among the last decade's scientific breakthroughs, achieving remarkable remissions in patients with B cell leukemias and lymphomas. Now, the engineered cell therapies are traversing disease indications into autoimmunity and resolving disease symptoms in patients with systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis.¹.

MeSH terms

Autoimmunity / immunology
Humans
Immunotherapy, Adoptive* / methods
Lupus Erythematosus, Systemic* / therapy
Neoplasms*
Receptors, Antigen, T-Cell / therapeutic use
T-Lymphocytes

Substances

CD19-specific chimeric antigen receptor
Receptors, Antigen, T-Cell